Stock Market Reviews

ACTU (Actuate Therapeutics, Inc.) News

Get the latest news, insights, and market updates on ACTU (Actuate Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Actuate Therapeutics to Present at The Citizens Life Sciences Conference
  CHICAGO and FORT WORTH, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Citizens Life Sciences Conference in Miami Beach, FL on Tuesday, March 1
  Mar 4, 2026 - $ACTU
• Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
  CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 2
  Feb 24, 2026 - $ACTU
• Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt
  Key Insights The considerable ownership by private equity firms in Actuate Therapeutics indicates that they...
  Feb 4, 2026 - $ACTU
• Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
  -Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate development of the elraglusib tablet in specific indications, including refractory melanoma and additional target solid tumor and hematologic cancers -Program builds on early clinical evidence of monotherapy activity observed in immune checkpoint inhibitor (CPI)-refractory metastatic melanoma in a previously completed trial CHICAGO and FORT WORTH, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ac
  Jan 21, 2026 - $ACTU
• Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026
  Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy aloneElraglusib combination reduced the risk of death by 38% compared with gemcitabine/nab-paclitaxel alone, with increased durable survival observed beyond 24 months CHICAGO and FORT WORTH, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage bioph
  Jan 12, 2026 - $ACTU
• Actuate Therapeutics Plans to Advance Elraglusib in Ewing Sarcoma After Phase 1 Data
  Actuate Therapeutics (ACTU) said Tuesday it plans to advance elraglusib in Ewing sarcoma and potenti
  Jan 6, 2026 - $ACTU
• Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
  Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) observed in a patient with relapsed/refractory metastatic neuroblastomaClinical responses and disease control observed in 15 of 40 patients with difficult-to-treat refractory pediatric cancers, including 10 of 19 patients treated with elraglusib plus cyclophosphamide/topotecanData support advancing clinical development of elraglusib in Ewing sarcoma and po
  Jan 6, 2026 - $ACTU
• Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?
  Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Dec 24, 2025 - $ACTU
• Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
  CHICAGO and FORT WORTH, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3β (GSK-3β), today announced that data from its Phase 2 study evaluating elraglusib in metastatic pancreatic cancer have been selected for an oral presentation at the 2026 Amer
  Dec 18, 2025 - $ACTU
• Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
  Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest that nuclear GSK-3β expression may help identify patients most likely to respond to treatment of a historically difficult-to-treat refractory disease CHICAGO and FORT WORTH, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of
  Dec 15, 2025 - $ACTU